ITM Isotope Technologies Munich SE
Garching (ots) - The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone Targeted Radionuclide Therapy and Diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone ...
ITM Isotope Technologies Munich SE
Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...
ITM Isotope Technologies Munich SE
Garching (ots) - - In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical development for treatment of NETs - Excellent pharmacokinetic properties ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of ...
ITG Isotope Technologies Garching GmbH
Garching (ots) - ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative radioisotopes - expands its nuclear reactor and technology network in line with its strategy to guarantee global security of supply. In May 2012, ITG - a fully-owned subsidiary of ITM Isotopen Technologien München AG (ITM) based in Germany - and NTP Radioisotopes SOC Ltd (NTP) - a ...